Insider Buying: Generation Bio Co. (NASDAQ:GBIO) Director Buys $120,759.36 in Stock

Generation Bio Co. (NASDAQ:GBIO) Director Anthony G. Quinn acquired 125,791 shares of Generation Bio stock in a transaction on Friday, January 10th. The stock was purchased at an average price of $0.96 per share, with a total value of $120,759.36. Following the purchase, the director now owns 214,286 shares of the company’s stock, valued at $205,714.56. The trade was a 142.14 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Generation Bio Trading Up 6.6 %

NASDAQ:GBIO opened at $0.95 on Friday. The stock’s 50 day simple moving average is $1.30 and its 200-day simple moving average is $2.11. Generation Bio Co. has a 12-month low of $0.75 and a 12-month high of $4.65. The firm has a market cap of $63.20 million, a P/E ratio of -0.43 and a beta of 2.72.

Hedge Funds Weigh In On Generation Bio

Several institutional investors have recently bought and sold shares of GBIO. SG Americas Securities LLC purchased a new stake in shares of Generation Bio in the third quarter valued at about $42,000. Cubist Systematic Strategies LLC boosted its holdings in Generation Bio by 91.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock valued at $54,000 after purchasing an additional 9,075 shares in the last quarter. American Century Companies Inc. increased its position in Generation Bio by 199.3% during the 2nd quarter. American Century Companies Inc. now owns 31,786 shares of the company’s stock worth $90,000 after purchasing an additional 21,167 shares during the period. Barclays PLC raised its stake in shares of Generation Bio by 165.5% during the 3rd quarter. Barclays PLC now owns 76,430 shares of the company’s stock worth $189,000 after buying an additional 47,639 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Generation Bio by 7.4% in the 2nd quarter. Rhumbline Advisers now owns 78,903 shares of the company’s stock valued at $222,000 after buying an additional 5,430 shares during the period. 95.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on GBIO shares. Needham & Company LLC decreased their price target on shares of Generation Bio from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Wedbush reiterated an “outperform” rating and set a $5.00 target price on shares of Generation Bio in a research note on Thursday, November 7th.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.